Trial Profile

A Phase 2a, Randomized, Open-Label Study to Evaluate Multiple Dosing Regimens of Subcutaneous ALXN1820 in Adult Participants With Sickle Cell Disease

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 15 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tarperprumig (Primary)
Indications Sickle cell anaemia
Focus Adverse reactions
Acronyms PHOENIX
Sponsors Alexion AstraZeneca Rare Disease

Most Recent Events

01 Aug 2024 Status changed from active, no longer recruiting to discontinued.
06 Oct 2023 Status changed from recruiting to active, no longer recruiting.
08 Mar 2023 Planned End Date changed from 15 Feb 2024 to 24 Jun 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com